MYOVANT SCIENC.
Share · BMG637AM1024 · MYOV · A2DFYA (XNYS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of MYOVANT SCIENC.
No Price
Company Profile for MYOVANT SCIENC. Share
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Company Data
Name MYOVANT SCIENC.
Company Myovant Sciences Ltd.
Symbol MYOV
Website
https://myovant.com
Primary Exchange 
NYSE
NYSE
WKN A2DFYA
ISIN BMG637AM1024
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO David C. Marek
Market Capitalization 3 Mrd.
Country United Kingdom
Currency USD
Employees 0,6 T
Address 11-12 St. James’s Square, SW1Y 4LB London
IPO Date 2016-10-27
Ticker Symbols
| Name | Symbol |
|---|---|
| NYSE | MYOV |
More Shares
Investors who hold MYOVANT SCIENC. also have the following shares in their portfolio:
